Phase 2 study of eribulin mesylate in combination with carboplatin in patients with advanced triple-negative breast cancer.

Abstract

e12551Background: Treatment of triple negative breast cancer (TNBC) remains one of the most challenging subtypes to treat because of the lack of specific therapies. In addition to the evaluation of platinum in the preoperative setting, studies in the metastatic setting further support that platinum may be active in metastatic TNBC. Another novel mitotic inhibitor currently being studied in this setting is eribulin.The aim of this Phase 2 study was to assess efficacy and safety of eribulin in combination with carboplatin as first-line therapy for locally recurrent or metastatic TNBC. Methods: Eligible patients were females with TNBC who had received one previous chemotherapy regimen in adjuvant setting (including an anthracycline and a taxane, but excluding platinum agents), an ECOG (PS) ≤ 1, and adequate hematological, renal and hepatic function. Patients received eribulin at 1.4 mg/m2 (IV over 2-5 minutes) on days 1 and 8 followed by carboplatin AUC5 (IV over 30 minutes) on day 1 every 21 days until dise...